Galectin Therapeutics reported $-8122000 in EBIT for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Bristol Myers Squibb BMY:US USD 2.74B 461M
Galectin Therapeutics GALT:US USD -8122000 1.54M
Gilead Sciences GILD:US USD 2.81B 784M
Idera Pharmaceuticals IDRA:US USD -3689000 1.68M
Intercept Pharmaceuticals ICPT:US USD -10144000 3.22M
Merk MRK:US USD 5.56B 156M
Regulus Therapeutics RGLS:US USD -7563000 388K
Vital Therapies VTL:US USD -20116000 494K
YTE INCY:US USD 118.25M 142.04M